RxDoctor Payments Data

Christopher Bradley, DO

Clinical Cardiac Electrophysiology · Southfield, MINPI 1659636140

Payments from drug & device makers

What this record shows

The money is spread across several categories — grants (51.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Medtronic at 57.3% of the total. Reporting peaked in 2019 at $34,991 and has fallen 93.3% since, to $2,359 in 2025.

$50,385in general payments, 2019–2025

Across 239 payments — averaging $210.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$29K
  • Abbott$14K
  • Boston Scientific$6K
  • Amgen$374
  • Philips North America LLC$292
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$220
  • plus $1K from 17 others

What the payments were for

  • Consulting fees$3001%
  • Grants$25,90151%
  • Travel & lodging$11,86724%
  • Food & beverage$12,31724%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$50,385 in reported general payments places this provider in the 75th percentile of 105 clinical cardiac electrophysiology providers in Michigan.

See all clinical cardiac electrophysiology providers in Michigan

Medicare billing

Part B allowed, 2024
$182,744
Medicare patients
673
Services billed
1,781

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban249$259,861
XareltoRivaroxaban55$66,529
EntrestoSacubitril/Valsartan15$27,855
Metoprolol Succinate208$4,097
Flecainide Acetate41$2,601
Diltiazem 24hr Er (Cd)Diltiazem Hcl31$1,344
Amiodarone Hcl35$1,259
Carvedilol71$882
Losartan Potassium78$844
Omeprazole50$644
Atorvastatin Calcium43$473
Bumetanide15$471
Lisinopril28$316
Furosemide50$297
Amlodipine Besylate23$202

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$104$259,861249 claims
Johnson & JohnsonXarelto$125$66,52955 claims
NovartisEntresto$54$27,85515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 105 clinical cardiac electrophysiology providers in Michigan.

Other clinical cardiac electrophysiology in Southfield

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →